Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLLLina van der Straten, Mark‐David Levin, Ilse Houtenbos et al.|Blood|2023Cited by 27
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort StudySammy Huygens, Bas B. Oude Munnink, Marion Koopmans et al.|Clinical Infectious Diseases|2024Cited by 15